Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

New tools could help detect wildlife disease outbreaks

Two new tools that enable the public to report sick or dead wild animals could also lead to the detection and containment of wildlife disease outbreaks that may pose a health risk to people.

26 Oct 2010

Eye-gaze technology opens world of communication for Rett Syndrome children

Special eye-gaze technology now being used in the Department of Neurology at The Children's Hospital at Montefiore (CHAM) is revealing the hidden, inner world of children who have Rett Syndrome, a rare and severe autism spectrum disorder that primarily affects little girls. It is a neurological disease in which mobility and autonomic functions are severely impaired, seizures and orthopedic problems are common, and the children lose functional hand use and the ability to speak.

26 Oct 2010

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced positive results from a Phase I/II challenge study of its norovirus virus-like particle (VLP) vaccine candidate.

26 Oct 2010

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today the results of a clinical trial of its investigational Fluzone Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

26 Oct 2010

Baxter announces launch of GLASSIA in the U.S.

Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.

From Baxter International Inc. 26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

CBER's Laboratory Quality System program receives accreditation

The U.S. Food and Drug Administration today announced that the American Association for Laboratory Accreditation has accredited the Laboratory Quality System program in the Center for Biologics and Evaluation Research (CBER) under ISO/IEC 17025 in the fields of biological and chemical testing.

26 Oct 2010

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

Inviragen, a company developing vaccines to protect against infectious diseases worldwide, and the Program for the Study and Control of Tropical Diseases (PECET), jointly announced the initiation of a Phase 1 clinical trial of DENVax™ in Colombia. DENVax is an investigational vaccine designed to provide protection against all four dengue virus serotypes. The trial will measure the safety of DENVax as well as the immune responses induced by the vaccine in healthy adults in Rionegro, Colombia.

25 Oct 2010

H1N1 linked to increased rate of empyema in children

The H1N1 influenza pandemic has led to a sharp increase in the number of children with a serious "secondary" bacterial infection called empyema in children, suggests a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

25 Oct 2010

New synthetic population can help computational modelers to study infectious diseases

To help computational modelers who study the spread of infectious diseases, including flu, researchers supported by the National Institutes of Health at RTI International in North Carolina created a synthetic population mirroring U.S. demographics. Now they've added another layer of realism: where the virtual citizens live.

25 Oct 2010

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.

25 Oct 2010

$Precautions needed against cold-related frostbite, ankle sprains and fractures$

Precautions needed against cold-related frostbite, ankle sprains and fractures

With cold weather on the horizon, podiatrists at Temple University's School of Podiatric Medicine warn that people of all ages need to take precautions to protect their feet from cold-related injuries like frostbite, ankle sprains and fractures.

25 Oct 2010

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a peer-reviewed research article describing the development of a new intradermal, minimally-invasive DNA vaccine delivery device was published in the prestigious journal Gene Therapy.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

Incidence of KPC-producing bacteria is rising in Chicago

In a survey of Chicago-area healthcare facilities, researchers at Rush University Medical Center and the Cook County Department of Public Health have found that the incidence of KPC-producing bacteria is rising. These bugs cause infections with high mortality rates and are resistant to the most commonly used antibiotics.

25 Oct 2010

State Watch: N.Y. approves rate hikes; Arizona referendum on health insurance mandate; Md. insurer cuts broker fees

The Sacramento Bee: "A Sacramento federal judge has ordered the state to keep providing adult dental, podiatric and chiropractic services to poor people in underserved rural areas until it gets permission from federal health authorities to discontinue the benefits. U.S. District Judge Frank C. Damrell Jr. ruled Wednesday that, while the services are not mandatory under the federal Medicaid program (Medi-Cal in California), the Legislature's decision to end them last year as a cost-saving measure was unlawful without federal approval.

25 Oct 2010

Taste receptors in lungs can revolutionize treatment option for asthma

Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.

25 Oct 2010

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.

25 Oct 2010

Maven Semantic updates Antiviral research database

Maven Semantic announces updates to their Antiviral research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

25 Oct 2010

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

Pharmaceutical company Pharmaxis today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.

25 Oct 2010

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

New tools could help detect wildlife disease outbreaks

Eye-gaze technology opens world of communication for Rett Syndrome children

LigoCyte presents Phase I/II study results of NoV vaccine for gastroenteritis at IDSA Meeting

Sanofi Pasteur presents Fluzone quadrivalent Phase II trial data for influenza at IDSA Annual Meeting

Baxter announces launch of GLASSIA in the U.S.

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

CBER's Laboratory Quality System program receives accreditation

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

H1N1 linked to increased rate of empyema in children

New synthetic population can help computational modelers to study infectious diseases

Beijing CDC selects Sinovac as first priority supplier of seasonal influenza vaccine

Precautions needed against cold-related frostbite, ankle sprains and fractures

Inovio announces publication of minimally-invasive intradermal device in journal Gene Therapy

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Incidence of KPC-producing bacteria is rising in Chicago

State Watch: N.Y. approves rate hikes; Arizona referendum on health insurance mandate; Md. insurer cuts broker fees

Taste receptors in lungs can revolutionize treatment option for asthma

Sinovac Biotech receives Drug Registration Certificate for seasonal influenza vaccine

Maven Semantic updates Antiviral research database

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in